The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 18, 2017
Filed:
Oct. 29, 2014
Applicant:
Cima Labs Inc., Brooklyn Park, MN (US);
Inventors:
Dinesh K. Haswani, Plymouth, MN (US);
Derek V. Moe, Mound, MN (US);
Victoria A. O'Neill, Wayzata, MN (US);
Manuel A. Vega Zepeda, Minnetonka, MN (US);
Assignee:
Cima Labs Inc., Brooklyn Park, MN (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/485 (2006.01); A61K 9/16 (2006.01); A61K 31/167 (2006.01); A61K 31/165 (2006.01); A61K 31/515 (2006.01); A61K 31/5513 (2006.01); A61K 31/135 (2006.01); A61K 31/437 (2006.01); A61K 31/554 (2006.01); A61K 31/137 (2006.01); A61K 31/4458 (2006.01); A61K 9/20 (2006.01); A61K 31/192 (2006.01); A61K 31/4402 (2006.01); A61K 31/616 (2006.01); A61K 9/00 (2006.01); A61K 31/16 (2006.01); A61K 9/50 (2006.01);
U.S. Cl.
CPC ...
A61K 31/485 (2013.01); A61K 9/0053 (2013.01); A61K 9/1676 (2013.01); A61K 9/2009 (2013.01); A61K 9/2013 (2013.01); A61K 9/2018 (2013.01); A61K 9/2027 (2013.01); A61K 9/2054 (2013.01); A61K 9/2063 (2013.01); A61K 9/2081 (2013.01); A61K 9/5015 (2013.01); A61K 9/5031 (2013.01); A61K 9/5047 (2013.01); A61K 31/135 (2013.01); A61K 31/137 (2013.01); A61K 31/16 (2013.01); A61K 31/165 (2013.01); A61K 31/167 (2013.01); A61K 31/192 (2013.01); A61K 31/437 (2013.01); A61K 31/4402 (2013.01); A61K 31/4458 (2013.01); A61K 31/515 (2013.01); A61K 31/554 (2013.01); A61K 31/5513 (2013.01); A61K 31/616 (2013.01); A61K 9/5026 (2013.01); A61K 9/5078 (2013.01);
Abstract
Described are immediate release oral dosage forms that contain abuse-deterrent features. In particular, the disclosed dosage forms provide deterrence of abuse by ingestion of multiple individual doses. In addition, the disclosed dosage forms provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses.